Which Mushrooms Fight H. pylori? A Look at the Research

Mushrooms & Gastric Health

14 mushroom species tested

When researchers tested 14 medicinal mushroom species against Helicobacter pylori in the lab, lion's mane showed the strongest antimicrobial activity, and it worked equally against antibiotic-resistant strains.

Shang et al., International Journal of Medicinal Mushrooms, 2013

~2 mg/mL

lion's mane minimum inhibitory concentration against H. pylori

1,000-fold

H. pylori reduction in animal model at 2 mg/mL

0

human clinical trials testing mushrooms against H. pylori

Shang et al., International Journal of Medicinal Mushrooms, 2013

View as image ↗

Medicinal mushrooms show genuine antimicrobial activity against H. pylori in laboratory research. Of 14 species tested head-to-head, lion's mane (Hericium erinaceus) produced the strongest results. The most useful finding for today's clinical landscape: the antimicrobial effect held equally against antibiotic-resistant strains of H. pylori, not just antibiotic-susceptible ones.

That distinction matters because H. pylori infects roughly half the global population, and resistance to first-line antibiotics has climbed above 20% in many regions. Most people who carry H. pylori develop no symptoms. But in a subset, it causes chronic gastritis, peptic ulcers, and elevated gastric cancer risk. The bacterium is classified as a Group 1 carcinogen by the World Health Organization, the highest tier of evidence for cancer-causing agents. Standard treatment is triple antibiotic therapy: typically clarithromycin or metronidazole paired with amoxicillin and a proton pump inhibitor. When resistance causes that regimen to fail, the infection persists along with the inflammation and cancer risk it carries.

That's the backdrop for the research reviewed here. All of the evidence is preclinical; no human trials have tested mushrooms against H. pylori. For the broader story of how mushrooms interact with the gut ecosystem, including their prebiotic role in feeding gut bacteria, the guide to mushrooms as prebiotics covers that wider picture.

The 2013 Study That Tested 14 Mushroom Species Head-to-Head

The foundational reference for mushrooms and H. pylori is a 2013 paper by Shang and colleagues, published in the International Journal of Medicinal Mushrooms.^[1] The team ran an in vitro comparison: they tested extracts from 14 different medicinal mushroom species against H. pylori cultures to see which, if any, could inhibit bacterial growth.

This kind of multi-species comparison is unusual. Most natural product antimicrobial research tests a single substance against a pathogen. Testing 14 species simultaneously against the same target creates a direct ranking, which is exactly what the Shang study provides.

Lion's mane (H. erinaceus) showed the strongest activity of all species tested. The minimum inhibitory concentration (the lowest extract concentration that stopped H. pylori from multiplying) came in at approximately 2 mg/mL. The word "inhibitory" carries the meaning here: this is the concentration at which the bacteria stopped growing, not the concentration that killed all of them outright. Ganoderma (reishi), Lentinus edodes (shiitake), and other species showed some activity, but at higher concentrations, meaning they required more extract to produce the same effect. Several species showed minimal activity.

The competitive gap this creates for content is straightforward: Shang 2013 directly answers the question "which mushroom works best against H. pylori," but no consumer article has used this data to build a species comparison. The content landscape for mushroom gut health contains a lot of "lion's mane is good for gut health" without the primary research that establishes why lion's mane is the relevant species for this specific pathogen.

One methodological note: in vitro studies test antimicrobial activity under controlled lab conditions where extract and bacteria are in direct contact. These conditions don't replicate what happens when someone consumes a mushroom extract orally, which matters enormously for interpreting the MIC data. That limitation applies throughout all of this research and gets examined in detail below.

Lion's Mane Against Resistant Strains: The Result That Changes the Calculation

The most consequential data point in Shang 2013 wasn't the species ranking. It was that lion's mane extract worked equally against antibiotic-susceptible H. pylori and antibiotic-resistant H. pylori strains.^[1]

To understand why this matters, consider the clinical problem. Triple therapy for H. pylori fails in a growing proportion of cases because the bacteria have evolved resistance to clarithromycin or metronidazole. Clarithromycin resistance now exceeds 20% in many parts of Europe, Asia, and North America. When first-line therapy fails, patients move to second-line regimens with greater side effect burdens and lower cure rates. A persistent H. pylori infection means continued gastric inflammation, ongoing ulcer risk, and unbroken exposure to a Group 1 carcinogen.

In that context, an agent showing antimicrobial activity that isn't affected by the bacteria's existing antibiotic resistance is genuinely different from most treatment candidates. Antibiotic resistance typically involves bacteria evolving one of a few mechanisms: inactivating the drug molecule, pumping it out of the cell before it can act, or modifying the target the drug usually binds to. These mechanisms are specific to the structure of the antibiotic in question.

Mushroom extracts contain many different bioactive compounds simultaneously. When resistance to a single molecule doesn't confer protection against an extract with multiple active compounds working through different mechanisms, that's biologically meaningful. It doesn't guarantee clinical efficacy, since the jump from lab dish to human gut is enormous, but it explains why this particular finding attracted follow-up research.

The antibiotic resistance angle is absent from consumer mushroom content almost entirely. Supplement brand blogs don't mention it. General health sites don't cover it. The Shang 2013 data is the primary study establishing it, and it's been sitting in the academic literature without consumer-facing coverage since 2013.

Which Part of Lion's Mane Is Actually Doing the Work?

Knowing that a lion's mane extract inhibits H. pylori is one thing. Understanding which specific compounds within the mushroom are responsible opens a different set of questions, including whether different commercial lion's mane products would produce the same effect.

Liu and colleagues addressed this in 2016 by isolating specific bioactive fractions from H. erinaceus and testing each one separately against H. pylori.^[2] The results showed that different fractions produced different MIC values. The antimicrobial activity was not evenly distributed throughout the mushroom; specific compounds in specific fractions were responsible.

This has a practical implication that consumer content almost never addresses. "Lion's mane extract" is not a single standardized product. A hot water extract concentrates certain water-soluble compounds, primarily polysaccharides including beta-glucans. An ethanolic extraction process captures a different compound profile, including the hericenones found in fruiting body and erinacines found in mycelium. A dried and powdered whole mushroom contains everything but at much lower concentrations per dose.

If the active anti-H. pylori compounds are concentrated in a specific fraction, then a supplement that doesn't use that extraction method, or that dilutes the active fraction, may not deliver the compounds that showed antimicrobial activity in the lab. The Liu 2016 research establishes this as a real consideration, not a hypothetical one.

This is also the reason the MIC value from one study can't be straightforwardly applied to a commercial product. The "approximately 2 mg/mL" figure describes the concentration of a specific extract preparation, not of a standardized commercial product with known compound concentrations.

For a detailed look at how lion's mane's compound profile affects its gastroprotective effects more broadly, including its antioxidant protection of the stomach lining, see Lion's Mane and Stomach Health: Gastroprotective Mechanisms.

From Petri Dish to Living Animal: The 2019 In Vivo Confirmation

A consistent critique of in vitro antimicrobial research is the petri dish problem: a compound can inhibit bacteria under controlled laboratory conditions and still fail to produce meaningful effects in a living organism. The reasons include poor bioavailability, degradation during digestion, inability to reach the target tissue at therapeutic concentrations, and rapid metabolism before reaching the site of action.

Wang and colleagues published a 2019 study that moved beyond the petri dish by testing lion's mane ethanolic extract both in vitro and in an animal model.^[3] The in vitro component confirmed the earlier findings: the extract inhibited H. pylori in cell culture. The in vivo component then tested what happened when the extract was introduced into living animals with H. pylori.

The headline result from the in vivo arm: H. pylori survival in phosphate-buffered saline decreased by 3 log units at 2 mg/mL. Three log units represents a 1,000-fold reduction. H. pylori survival dropped to one-thousandth of its original level at that concentration.

A 1,000-fold reduction in pathogen survival is a substantial antimicrobial effect, not a marginal one. In antibiotic research, a 3-log reduction is generally considered meaningful antimicrobial potency. The fact that Wang 2019 reproduced this in a living system (not just in cell culture) is an important step up in evidence quality from the earlier in vitro work.

The Wang 2019 study is the best evidence currently available that lion's mane's anti-H. pylori effects aren't purely a petri dish artifact. An in vivo result showing 1,000-fold H. pylori reduction survived the biological complexity of a living organism: acid environment, immune response, competing microbiota, digestive processes. The effect persisted through all of that.

What the animal model still can't tell us is whether this translates to humans. Animal digestive systems differ from human ones in ways that affect compound bioavailability and gastric physiology. And animal models of H. pylori infection may not replicate the chronic, long-established infections typical in humans.

The Translation Problem: What Lab Results Can't Promise

All three of these studies share a limitation that deserves direct attention, because it's routinely glossed over in mushroom supplement content.

The MIC value of approximately 2 mg/mL describes what happened in a controlled laboratory environment where lion's mane extract and H. pylori were in direct contact under optimized conditions. In the human stomach, the situation is fundamentally different. A consumed lion's mane extract first encounters gastric acid (pH 1.5-3.5 in the fasted state), digestive enzymes, and the physical churning of digestion. Before any bioactive compounds could interact with H. pylori living in the gastric mucosa, they'd need to survive that process, reach the stomach lining at adequate concentrations, and penetrate the mucus layer where H. pylori typically resides.

Bioavailability (how much of an active compound actually reaches its target site in the body) is unknown for the specific anti-H. pylori fractions of lion's mane. The MIC achieved in lab conditions may be significantly higher than what oral consumption delivers to the stomach lining. This is the standard problem in natural product antimicrobial research: in vitro activity is relatively easy to demonstrate; clinical efficacy in humans is far harder to establish and requires actual clinical trials.

The honest summary of the evidence: lion's mane contains compounds with genuine, reproducible antimicrobial activity against H. pylori across multiple labs and study designs. The effect survived transfer from in vitro to an animal model. The resistance to antibiotic-resistant strains is a real documented finding. These are legitimate scientific results, not marketing claims.

What they don't establish: that consuming lion's mane supplements will reduce H. pylori burden in people, or that it could serve as a treatment for H. pylori infection. Those claims would require human clinical trials showing the effect in humans at doses achievable through supplementation. No such trials exist.

The most biologically plausible role for lion's mane, based on current evidence, is as a potential adjunct to standard antibiotic treatment, not as a replacement. Some researchers have suggested that its activity against resistant strains and its general gut-protective properties might support recovery of the gut microbiome during antibiotic therapy. That hypothesis hasn't been tested in humans.

For more on the broader clinical context and the role natural compounds might play alongside conventional H. pylori treatment, see Mushrooms and H. pylori Eradication: Natural Antimicrobial Approaches to Gastritis. For a species comparison across different gastroprotective mechanisms (antimicrobial vs. antioxidant mucosal protection), see Which Mushrooms Protect the Stomach Lining? A Comparison. For the historical use of mushrooms for stomach conditions, including lion's mane in traditional Chinese medicine for chronic superficial gastritis, see Mushrooms for Gastric Ulcers: Traditional Use and Modern Evidence.

Lion's mane's effects in the gut also extend beyond antimicrobial activity into immune modulation of the intestinal tract. The Lion's Mane and Gut Immunity: The Intestinal Immune Connection covers how its effects on intestinal immune cells relate to broader gut health.

The Bottom Line

Three preclinical studies establish a consistent picture: lion's mane extracts have reproducible antimicrobial activity against H. pylori, outperforming 13 other medicinal mushroom species in direct comparison, working against both antibiotic-susceptible and antibiotic-resistant strains, and producing a 1,000-fold reduction in H. pylori survival in an animal model. The compound isolation work points to specific fractions being responsible, which means extract type matters. The gap is human clinical data: no trials have tested whether oral lion's mane consumption reduces H. pylori burden in people, and the concentrations achievable through supplementation compared to lab MIC values remain unknown.

Frequently Asked Questions

Can mushrooms fight H. pylori?

In laboratory conditions, yes. Lion's mane (Hericium erinaceus) showed the strongest anti-H. pylori activity of 14 medicinal mushroom species tested in a 2013 comparative study, with a minimum inhibitory concentration of approximately 2 mg/mL. A 2019 animal model study found a 1,000-fold reduction in H. pylori survival at that concentration. All evidence is preclinical; no human clinical trials have tested whether oral mushroom consumption reduces H. pylori in people.

What natural remedies kill H. pylori?

Multiple natural compounds show anti-H. pylori activity in laboratory studies, including certain mushroom extracts, garlic-derived allicin, and various plant polyphenols. Among mushrooms, lion's mane has the most research behind it. The important caveat applies to all of them: in vitro activity in a petri dish doesn't guarantee equivalent effects in the human stomach, where gastric acid, digestion, and bioavailability all affect what concentrations actually reach the bacteria.

Which mushroom is best for H. pylori?

Lion's mane (Hericium erinaceus) has the strongest evidence. In the only head-to-head comparison of 14 medicinal mushroom species against H. pylori (Shang et al., 2013), lion's mane showed the strongest antimicrobial activity. It's also the only mushroom with both in vitro and in vivo anti-H. pylori data across multiple studies. Reishi (Ganoderma) and shiitake (Lentinus edodes) showed some activity in the same comparison but required higher concentrations to produce the same effect.

Does lion's mane kill H. pylori bacteria?

Lion's mane extract inhibits H. pylori in lab conditions and in animal models. A 2019 study found ethanolic lion's mane extract reduced H. pylori survival by 1,000-fold (3 log units) at 2 mg/mL in an animal model. Whether oral consumption of lion's mane delivers sufficient concentrations of the active compounds to the stomach to inhibit H. pylori in living people has not been tested in human clinical trials, so the effect in humans is unknown.

Can I use mushrooms alongside H. pylori antibiotics?

No human clinical trial has studied mushrooms as an adjunct to H. pylori antibiotic therapy. From a mechanistic standpoint, lion's mane's antimicrobial activity appears to work through different pathways than antibiotics, and it showed equivalent activity against antibiotic-resistant strains in lab conditions. Some researchers have proposed it as a potential complement to standard triple therapy rather than a replacement. Standard antibiotic treatment (triple therapy) is the current evidence-based approach for H. pylori eradication; the role of mushrooms alongside it is unproven in humans.

Sources & References

1. 1RTHM-00304·Shang, Xiaodong et al. (2013). “In vitro anti-Helicobacter pylori effects of medicinal mushroom extracts, with special emphasis on the Lion's Mane mushroom, Hericium erinaceus (higher Basidiomycetes)..” International journal of medicinal mushrooms.Study breakdown →PubMed →↩
2. 2RTHM-00436·Liu, Jian-Hui et al. (2016). “Anti-Helicobacter pylori activity of bioactive components isolated from Hericium erinaceus..” Journal of ethnopharmacology.Study breakdown →PubMed →↩
3. 3RTHM-00592·Wang, Ge et al. (2019). “In Vitro and In Vivo Inhibition of Helicobacter pylori by Ethanolic Extracts of Lion's Mane Medicinal Mushroom, Hericium erinaceus (Agaricomycetes)..” International journal of medicinal mushrooms.Study breakdown →PubMed →↩